Thomas Dresing, MD
Cardiovascular Disease · Cleveland, OHNPI 1770513640
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 77.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $14,856 and has fallen 97.9% since, to $319 in 2024.
Across 23 payments — averaging $692.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Boston Scientific$3K
- Abbott$628
- Atricure, Inc.$143
- Impulse Dynamics (USA) Inc.$110
- Kestra Medical Technology Services, Inc.$26
- plus $13 from 1 others
Across 8 payments — averaging $1955.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$16K
What the payments were for
- Speaking & faculty fees$7,30046%
- Travel & lodging$7,09145%
- Food & beverage$1,54310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 8 | $12,294 |
| Boston Scientific | 4 | $2,720 |
| Abbott | 7 | $628 |
| Atricure, Inc. | 1 | $143 |
| Impulse Dynamics (USA) Inc. | 1 | $110 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,934 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 429 | $572,907 |
| XareltoRivaroxaban | 162 | $187,437 |
| Dofetilide | 173 | $52,170 |
| Flecainide Acetate | 83 | $4,325 |
| Metoprolol Succinate | 228 | $4,252 |
| Nebivolol Hcl | 29 | $2,662 |
| Amiodarone Hcl | 71 | $1,370 |
| SotalolSotalol Hcl | 48 | $1,335 |
| Nadolol | 17 | $1,122 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 34 | $1,044 |
| Betaxolol Hcl | 26 | $943 |
| Sotalol AfSotalol Hcl | 11 | $678 |
| Spironolactone | 30 | $450 |
| Warfarin Sodium | 53 | $391 |
| Digoxin | 12 | $340 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Steven NissenCleveland$149K
- Daniel CantillonCleveland$140K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.